Aldeyra Therapeutics Inc (NASDAQ:ALDX) has been given an average recommendation of “Buy” by the eight research firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $18.33.
A number of brokerages have commented on ALDX. Zacks Investment Research downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. ValuEngine raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Seaport Global Securities assumed coverage on shares of Aldeyra Therapeutics in a research report on Friday, January 26th. They set a “buy” rating and a $13.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Aldeyra Therapeutics in a research report on Tuesday, October 24th. They set an “overweight” rating and a $22.00 price target for the company.
Aldeyra Therapeutics (NASDAQ ALDX) opened at $7.10 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.35 and a current ratio of 20.35. Aldeyra Therapeutics has a 52 week low of $3.80 and a 52 week high of $11.90. The company has a market cap of $135.74, a PE ratio of -5.04 and a beta of 0.59.
Several institutional investors and hedge funds have recently made changes to their positions in ALDX. Vanguard Group Inc. increased its position in shares of Aldeyra Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after acquiring an additional 9,407 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Aldeyra Therapeutics during the second quarter valued at about $104,000. Bank of New York Mellon Corp acquired a new stake in shares of Aldeyra Therapeutics during the third quarter valued at about $134,000. Sphera Funds Management LTD. grew its holdings in shares of Aldeyra Therapeutics by 19.2% in the third quarter. Sphera Funds Management LTD. now owns 1,044,131 shares of the biotechnology company’s stock valued at $7,518,000 after purchasing an additional 168,200 shares in the last quarter. Finally, Perceptive Advisors LLC grew its holdings in shares of Aldeyra Therapeutics by 6.9% in the third quarter. Perceptive Advisors LLC now owns 3,085,458 shares of the biotechnology company’s stock valued at $22,215,000 after purchasing an additional 200,000 shares in the last quarter. Institutional investors and hedge funds own 47.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Aldeyra Therapeutics Inc (ALDX) Receives Average Rating of “Buy” from Analysts” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/03/aldeyra-therapeutics-inc-aldx-receives-average-rating-of-buy-from-analysts.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.